camrelizumab
jiangsu hengrui pharmaceuticals
['nsclc', 'impower,10', 'sclc', 'check,mate,078', 'ca,022,i', 'ca,022,1', 'adagrasib', ' cam ', ' rome', 'cisplatin', 'atezo', 'nivo', 'paclitaxel', 'ca,022,001', 'impower010', 'check,mate,816', 'thoracic', 'checkmate 816', 'pembro', 'porter', 'award', 'nivolumab', 'check,mate,276', 'melanoma', 'albumin,bound,paclitaxel', 'check,mate,227', 'lung', 'nadim ii', 'camrelizumab']
#esmoimmuno22: neoadjuvant camrelizumab plus chemotherapy improves pathologic complete response in stage iiia and b #nsclc 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.